SENTINEL – Novel injectable biosensor for continuous remote monitoring of cancer patients at high-risk of relapse
Remote patient monitoring (RPM) of cancer diseases can be potentially used to increase current predictive rates, while contributing for a more cost-effective and accessible diagnosis and treatment. Patients at high risk of cancer recurrence would constitute an ideal population for such improved cancer monitoring tools. These novel tools should have the ability to remotely monitor patient data, which should be used to detect disease onset or progression. While RPM has been predominantly applied for monitorization of vital signs, the extension of such concept to monitorization of high-risk profile patients would constitute a significant jump forward in the prevention and early diagnosis of cancer patients.
SENTINEL project proposes the breakthrough development of remote monitoring tools for high-risk profile cancer patients. Such technology aims to increase the positive predictive value (PPV) of cancer screening, while facilitating the remote and ubiquitous monitoring of patients in large scale. The main objective of the SENTINEL project is to develop a minimally invasive and biocompatible implantable biosensor to be used in the early tumor surveillance in post-operative prostate cancer patients.
Main Project Outcomes
S. Queirós, “Right ventricular segmentation in multi-view cardiac MRI using a unified U-net model”, in E. Puyol Antón et al. (eds) Statistical Atlases and Computational Models of the Heart. Multi-Disease, Multi-View, and Multi-Center Right Ventricular Segmentation in Cardiac MRI Challenge. STACOM 2021. Lecture Notes in Computer Science, vol 13131, pp. 287-295, Springer, Cham, 2022.
“Best Paper Award in the M&Ms-2 Challenge”, by M&Ms2 Challenge organizers and the Medical Image Computing and Computer Assisted Intervention (MICCAI) Society.